A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.

Trial Profile

A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Exemestane (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ExCel
  • Most Recent Events

    • 13 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 13 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 10 Dec 2011 Quality-of-life analysis presented at the 34th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top